Why an FDA decision on Stealth's Barth drug could ripple through the rare disease field

Retrieved on: 2025-08-26 17:41:31

Tags for this article:

Food and Drug Administration

Priority review

Stealth

Lindsay Marjoram

STEALTH BIOTHERAPEUTICS

Reenie McCarthy

Click the tags to see associated articles and topics

Why an FDA decision on Stealth's Barth drug could ripple through the rare disease field. View article details on hiswai:

Excerpt

Adeline Kon / BioPharma Dive/BioPharma Dive. Image attribution tooltip. Deep Dive // Patent thickets. Drug patents protect pharma profits. Track when ...

Article found on: www.biopharmadive.com

View Original Article